CRYSTALLINE (2S,4R)-5-(5'-CHLOR-2'-FLUORO-[1,1'-BIPHENYL]-4-YL)-2-(ETHOXYMETHYL)-4-(3-HYDROXYISOXAZOL-5-CARBOXAMIDO)-2-METHYLPENTANIC ACID AND ITS APPLICATIONS Russian patent published in 2021 - IPC C07D261/18 A61K31/42 A61P9/00 

Abstract RU 2756223 C2

FIELD: chemistry.

SUBSTANCE: invention relates to a method for producing a crystalline form of (2S,4R)-5-(5'-chlor-2'-fluoro-[1,1'-biphenyl]-4-yl)-2-(ethoxymethyl)-4-(3-hydroxyisoxazol-5-carboxamido)-2-methylpentanic acid, including (a) forming a solution including (2S,4R)-5-(5'-chlor-2'-fluoro-[1,1'-biphenyl]-4-yl)-2-(ethoxymethyl)-4-(3-hydroxyisoxazol-5-carboxamido)-2-methylpentanic acid and a mixture of ethyl acetate and water, ethyl acetate or ethanol at an increased temperature; (b) cooling the solution to a temperature between about -20°C and 5°C; and (c) isolating obtained solids with obtaining a crystalline form. The solution from the stage (a) additionally contains a metal acceptor, such as SiliaMetS® Thiol. A temperature at the stage (a) is between about 60°C and 95°C. Isolating solids at the stage (c) includes filtering, washing with one or several solvents, drying in the air or in a vacuum or a combination of these stages. Drying in a vacuum is carried out at a temperature between 25°C and 70°C.

EFFECT: crystalline form of (2S,4R)-5-(5'-chlor-2'-fluoro-[1,1'-biphenyl]-4-yl)-2-(ethoxymethyl)-4-(3-hydroxyisoxazol-5-carboxamido)-2-methylpentanic acid having stability, high melting point and low hygroscopicity.

7 cl, 10 dwg, 9 tbl, 6 ex

Similar patents RU2756223C2

Title Year Author Number
(2S,4R)-5-(5'-CHLORO-2'-FLUOROBIPHENYL-4-YL)-4-(ETHOXYOXALYLAMINO)-2-HYDROXYMETHYL-2-METHYLPENTANOIC ACID 2016
  • Hughes Adam D.
  • Fenster Erik
  • Fleury Melissa
  • Beausoleil Anne-Marie
  • Thalladi Venkat R.
  • Nzerem Jerry
  • Rapta Miroslav
RU2726623C2
(2R,4R)-5-(5'-CHLORO-2'-FLUOROBIPHENYL-4-YL)-2-HYDROXY-4-[(5-METHYLOXAZOLE-2-CARBONYL)AMINO]PENTANOIC ACID 2016
  • Fleury Melissa
  • Hughes Adam D.
  • Beausoleil Anne-Marie
  • Fenster Erik
  • Thalladi Venkat R.
  • Rapta Miroslav
RU2715241C2
SUBSTITUTED AMINOBUTYRIC DERIVATIVES AS NEPRILYSIN INHIBITORS 2012
  • Fleri Melissa
  • Gendron Roland
  • Khjuz Adam D.
RU2604522C2
NEPRILYSIN INHIBITORS 2013
  • Fleri Melissa
  • Khyuz Adam D.
RU2650114C2
NEPRILYSIN INHIBITORS 2011
  • Smit Kameron
  • Fleri Melissa
  • Gendron Roland
  • Khadson Rajan
  • Khjuz Adam D.
RU2605557C2
INHIBITORS OF NONPRILYZINE 2011
  • Gendron Roland
  • Fleri Melissa
  • Khyuz Adam D.
RU2622288C2
PHARMACEUTICAL COMBINATIONS OF ANGIOTENSIN RECEPTOR ANTAGONIST AND NEP INHIBITOR 2006
  • Fehn Lili
  • Godtfredsen Sven Ehrik
  • Karpinski P'Otr
  • Satton Pol Allen
  • Prashad Makhavir
  • Girgis Majkl Dzh.
  • Sjuj Bin'
  • Lju Jugan
  • Blehklok Tomas Dzh.
RU2503668C2
PHARMACEUTICAL COMBINATIONS OF ANGIOTENSINE RECEPTOR ANTAGONIST AND NEP INHIBITOR 2006
  • Fehn Lili
  • Godtfredsen Sven Ehrik
  • Karpinski P'Otr
  • Satton Pol Allen
  • Prashad Makhavir
  • Girgis Majkl Dzh.
  • Sjuj Bin'
  • Lju Jugan
  • Blehklok Tomas Dzh.
RU2459809C2
NEPRILYSIN INHIBITORS 2012
  • Khyuz Adam
  • Fenster Erik
  • Fleri Melissa
  • Gendron Roland
  • Moran Edmund Dzh.
RU2629930C2
PHARMACEUTICAL COMPOSITIONS INCLUDING VALSARTAN AND INHIBITORS OF NEUTRAL ENDOPEPTITAS (NEP) 2003
  • Uehbb Randi Li
  • Ksander Gehri Majkl
RU2334513C2

RU 2 756 223 C2

Authors

Hughes, Adam D.

Fleury, Melissa

Rapta, Miroslav

Thalladi, Venkat R.

Fass, Gene Timothy

Simeone, Michael

Baldwin, R. Michael

Bourdet, David L.

Dates

2021-09-28Published

2017-03-07Filed